Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

63.04USD
23 Apr 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$63.04
Open
$62.07
Day's High
$63.35
Day's Low
$61.89
Volume
10,286,569
Avg. Vol
7,684,959
52-wk High
$79.61
52-wk Low
$60.32

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  GILD.O Industry Sector
P/E (TTM): 8.92 69.30 32.55
EPS (TTM): 9.21 -- --
ROI: 27.00 8.91 13.83
ROE: 63.92 10.06 15.25

Gilead teams up with insitro for experimental NASH treatments

Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.

Apr 16 2019

Gilead teams up with insitro for experimental NASH treatments

April 16 Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.

Apr 16 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Apr 12 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN, April 12 Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Apr 12 2019

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

Apr 08 2019

UPDATE 2-GSK wins U.S. nod for two-drug HIV combination

April 8 GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

Apr 08 2019

Trade hopes lift Wall Street; S&P 500 notches best quarter since 2009

NEW YORK U.S. stocks ended the final trading day of the first quarter on a strong note on Friday and the S&P 500 posted its best quarterly gain since 2009, boosted by optimism over the latest round of trade talks between the United States and China.

Mar 29 2019

U.S. moves to toss Gilead whistleblower lawsuit over HIV drugs

The U.S. Justice Department has moved to dismiss a closely watched whistleblower lawsuit accusing Gilead Sciences Inc of covertly arranging to have key ingredients for HIV medications made at a Chinese facility that had quality control issues.

Mar 29 2019

Gilead misses key goal in NASH liver disease trial, shares sink

CHICAGO Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

Feb 11 2019

Gilead misses key goal in NASH liver disease trial, shares sink

CHICAGO, Feb 11 Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

Feb 11 2019

Earnings vs. Estimates